Michael J. Pontecorvo, PhD, of Eli Lilly’s Avid Radiopharmaceuticals and colleagues at numerous medical institutions sent 618 patients for florbetapir (¹⁸F) PET neuroimaging, then randomized them 1:1 for amyloid assessment either immediately (information group) or after one year (control group). {read more here}